Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.96 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.96 |
| ▸ | TSHR | P16473 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38719 | 0.98 | ALDH1A1 (1.00) | ALDH1A1TSHRLMNAGAAMAPK1 | |
| SCHEMBL30343310 | 0.96 | ALDH1A1 (0.96) | ALDH1A1TSHRLMNAGAAMAPK1 | |
| SCHEMBL25308455 | 0.96 | ALDH1A1 (0.96) | ALDH1A1TSHRLMNAGAAMAPK1 | |
| SCHEMBL25307340 | 0.96 | ALDH1A1 (0.96) | ALDH1A1TSHRLMNAGAAMAPK1 | |
| SCHEMBL25262628 | 0.96 | ALDH1A1 (0.96) | ALDH1A1TSHRLMNAGAAMAPK1 | |
| Boric Acid SCHEMBL9665661 | 0.92 | ALDH1A1 (0.89) | ALDH1A1TSHRLMNAGAAMAPK1 | |
| SCHEMBL11636500 | 0.92 | ALDH1A1 (0.89) | ALDH1A1TSHRLMNAGAAMAPK1 | |
| SCHEMBL9345626 | 0.91 | ALDH1A1 (0.86) | ALDH1A1TSHRLMNAGAAMAPK1 | |
| Hydrochloric Acid SCHEMBL8844291 | 0.88 | ALDH1A1 (0.75) | ALDH1A1TSHRLMNAGAAMAPK1 | |
| Catechol SCHEMBL9664944 | 0.88 | ALDH1A1 (0.80) | ALDH1A1TSHRLMNAGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5085932-A | — | — | None | — | — | JP | disclosed |
| US-20240409563-A1 | HIGH PURITY POLYSILOXANE MACROMERS AND METHOD FOR MAKING THE SAME | GELEST, INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4448536-A1 | HIGH PURITY POLYSILOXANE MACROMERS AND METHOD FOR MAKING THE SAME | GELEST, INC. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401532-A | High-purity polysiloxane macromer and preparation method thereof | 盖列斯特有限公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2023113779-A1 | HIGH PURITY POLYSILOXANE MACROMERS AND METHOD FOR MAKING THE SAME | GELEST, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230183273-A1 | HIGH PURITY POLYSILOXANE MACROMERS AND METHOD FOR MAKING THE SAME | GELEST, INC. | 2023-06-15 | — | — | US | disclosed |
| US-9018332-B2 | Polyorganosiloxane containing methacryloxy group or acryloxy group and method for producing the same | DOW CORNING TORAY COMPANY, LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-20110092660-A1 | Polyorganosiloxane Containing Methacryloxy Group Or Acryloxy Group And Method For Producing The Same | DOW CORNING TORAY COMPANY, LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2251370-A1 | POLYORGANOSILOXANE CONTAINING METHACRYLOXY GROUP OR ACRYLOXY GROUP AND METHOD FOR PRODUCING THE SAME | Dow Corning Toray Co., Ltd. (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-6197988-B1 | DECOMPOSITION IN PRESENCE OF LEWIS ACID METAL HALIDE | DOW CORNING TORAY SILICONE CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0722723-A2 | Phenol derivatives for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0680755-A1 | Method for treating inflammation, ischemia-induced cell damage and muscular dystrophy | ELI LILLY AND COMPANY (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0474403-B1 | Method of treating inflammatory bowel disease | LILLY CO ELI (US) | 1995-05-10 | — | — | EP | disclosed |
| US-5393786-A | Administering certain phenolic compounds | ELI LILLY AND COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| US-5281623-A | Administering amino substituted phenolic derivatives as antiinflammatory or antiarthritic agents | ELI LILLY AND COMPANY (US) | 1994-01-25 | — | — | US | disclosed |
| US-5280046-A | Using an amide containing phenol compound | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1994-01-18 | — | — | US | disclosed |
| JP-H0585932-A | THERAPEUTIC MEDICINE FOR TYPE I DIABETES | UNIV COLORADO FOUND INC | 1993-04-06 | — | — | JP | disclosed |
| EP-0500336-A1 | Composition containing certain phenol and benzamide for the treatment of type I diabetes | UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0476846-A2 | Method for treating imflammation, ischemia-induced cell damage and muscular dystrophy | ELI LILLY AND COMPANY (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0474403-A1 | Method of treating inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1992-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409563-A1 | HIGH PURITY POLYSILOXANE MACROMERS AND METHOD FOR MAKING THE SAME | SSRP1, RPLP2, RPLP1 | GAA 3157/4885CA2 3843/4885ALDH1A1 837/4885 |
| US-20230183273-A1 | HIGH PURITY POLYSILOXANE MACROMERS AND METHOD FOR MAKING THE SAME | SSRP1, RPLP2, RPLP1 | GAA 3157/4885CA2 3843/4885ALDH1A1 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.